We are deeply grateful to California Institute for Regenerative Medicine (CIRM) for their support in raising awareness and providing the funding, guidance, and support needed on our journey to develop treatments for CMT4J and other genetic diseases. -Together, we will turn the impossible into possible!-
In December 2023, CIRM awarded Elpida Therapeutics a $3.9 million grant to support their groundbreaking work on Charcot-Marie-Tooth disease type 4J (CMT4J). CMT4J is an ultra-rare, inherited disorder that severely affects nerves and motor function, with no available treatments or cures. By funding this preclinical study, CIRM is helping to close critical knowledge gaps and accelerate the development of new stem cell and gene therapies. Learn more about CMT4J and what Elpida is doing to advance research forward. #CMT4J #RegenerativeMedicine #CIRM #RareDiseases #RareDisease #Preclinical #StemCells #GeneTherapies